2022

• Hauck, D., Nery, L., O'Connell, R., Clifton-Bligh, R., Mather, A., Girgis, C. (2022). Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: A 15-year single-centre experience. Bone Reports, 16, 101178. [More Information]
• Lee, V., Mather, A. (2022). The Renal System - Systems of the Body Series. United States: Elsevier.

2014

• Gangadharan Komala, M., Mather, A. (2014). Empagliflozin for the treatment of Type 2 diabetes. Expert Review of Clinical Pharmacology, 7(3), 271-279. [More Information]
• Gangadharan Komala, M., Gross, S., Mudaliar, H., Huang, C., Pegg, K., Mather, A., Shen, S., Pollock, C., Panchapakesan, U. (2014). Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice. PloS One, 9(11), 1-12. [More Information]

2013

• Panchapakesan, U., Pegg, K., Gross, S., Gangadharan Komala, M., Mudaliar, H., Forbes, J., Pollock, C., Mather, A. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy? PloS One, 8(2), 1-8. [More Information]
• Panchapakesan, U., Mather, A., Pollock, C. (2013). Role of glp-1 and dpp-4 in diabetic nephropathy and cardiovascular disease. Clinical Science, 124(1), 17-26. [More Information]
• Gangadharan Komala, M., Panchapakesan, U., Pollock, C., Mather, A. (2013). Sodium glucose cotransporter 2 and the diabetic kidney. Current Opinion In Nephrology And Hypertension, 22(1), 113-119. [More Information]

2011

• Mather, A., Pollock, C. (2011). Glucose handling by the kidney. Kidney International, 79(Suppl 120), S1-S6. [More Information]

2010

• Mather, A., Pollock, C. (2010). Renal glucose transporters: novel targets for hyperglycemia management. Nature Reviews Nephrology, 6(5), 307-11. [More Information]

2009

• Mather, A., Chen, X., McGinn, C., Field, M., Sumual, S., Mangiafico, S., Zhang, Y., Kelly, D., Pollock, C. (2009). High glucose induced endothelial cell growth inhibition is associated with an increase in TGF-{beta}(1) secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway. International Journal of Biochemistry and Cell Biology, 41(3), 561-569. [More Information]

2006

• Pollock, C., Mather, A. (2006). A current understanding of the pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzymeA reductase inhibitors on vascular disease. Current Topics in Pharmacology, 10(2), 89-97.